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Brain and CNS cancer are rare in comparison to other types of cancer. 
Currently there are no effective therapies for their treatment. In this study, 
meta-analysis of microarray datasets of Brain and CNS cancer was done to 
obtain significantly upregulated genes with increased statistical power and 
generalizability.  A total of 130 significantly up-regulated genes were obtained. 
Some of the genes found during analysis have not yet been associated with this 
cancer. Different biological networks were created and analyzed using the 
significantly up-regulated genes as input. For each network, the most 
significant pathways have also been identified computationally.  
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1. INTRODUCTION  
Brain and CNS cancer are classified as heterogenous tumors on genetic and biological basis [1]. These 
cancers comprise for approximately 3% of worldwide cancer cases. Though these are rare, there are no effective 
therapies for their treatment because of the relatively inaccessible location. They have been reported to be more 
commonly observed in men as compared to women [2]. With the variation in age as well as histological type, 
the prognoses of brain and CNS cancers differs significantly. Prognosis is significantly poor for old aged people 
and people suffering from glioblastomas [3]. The increased rate of survival in higher income countries can be 
directly linked to improvement in medical care as well as availability of new therapies [4][5]. Various studies 
have reported an increase in occurrence of brain and CNS cancers in elderly population of Western countries 
[6][7][8]. The risk of this cancer increases with certain genetic factors and ionizing radiation exposure, while 
allergic conditions seem to decrease the risk [9] [10]. European countries have the highest rates of brain and 
CNS cancer while Asian countries have the lowest. This difference can be partially linked to the difference in 
genetic background of the population in these continents [11]. The recent World Health Organization report 
(2016) includes classification of brain tumors and mentions molecular markers to determine subclasses of 
gliomas and medulloblastomas. But still very few markers are sufficiently characterized to impact the clinical 
practice in patients with CNS cancers. Through this paper we aim to predict the genes that are significantly up-
regulated and the corresponding pathways that play a significant role in CNS cancers. 
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2. RESEARCH METHOD  
 
2.1. Brain and CNS cancer microarray datasets 
       In this study, four brain and CNS cancer datasets (Table 1.) were selected from Oncomine [12] database. 
These datasets contained a differential analysis of tumor and normal samples, experiment type was mRNA and 
number of samples in both tumor and normal category was more than one. Oncomine [12] currently contains 
715 datasets (Oncomine _Research Edition) and it is one of the most comprehensive cancer-specific database. 
The major advantage of using this database is that prior to inclusion in Oncomine database, the microarray 
datasets obtained from public resources such as Stanford Microarray Database and the NCBI Gene Expression 
Omnibus or literature sources are reviewed by a panel of experts to ensure that they meet certain quality  
standards [13]. 
 
Table 1. Brain and CNS cancer microarray datasets included in the study 
Dataset name* Accession id Genes** Platform Dataset summary* 
Bredel Brain 2 GSE2223 14386 Platform not pre-
defined in 
Oncomine 
 
Fifty (50) brain CNS 
carcinoma samples and 4 
normal brain samples 
were analyzed on cDNA 
microarrays. Sample data 
includes disease type. 
 
Lee Brain GSE4536 19574 
 
 
 
Human Genome 
U133 Plus 2.0 Array 
 
Ninety-eight (98) brain 
and CNS cancer (26 of 
which are cell lines) and 
3 normal neural stem cell 
samples were analyzed 
on Affymetrix U133 Plus 
2.0 microarrays. Sample 
data includes type, 
growth media, cell line 
name, and passage. 
 
Liang Brain GSE4058 9957 
 
Platform not pre-
defined in 
Oncomine 
  
Thirty (30) glioblastoma, 
3 mixed astrocytoma-
oligodendroglioma, 2 
oligodendroglioma, 2 
normal brain, and 1 
normal cerebellum 
sample were analyzed on 
cDNA microarrays. 
Sample data includes 
type, age, location, 
primary/recurrent, sex, 
and survival. 
 
Murat Brain GSE7696 19574 
 
Human Genome 
U133 Plus 2.0 Array 
Eighty (80) glioblastoma 
samples and 4 normal 
brain tissue samples were 
analyzed. Sample data 
includes sample 
recurrence status, age, 
sex, MGMT methylation 
status, and survival 
status. 
 
*As identified by the Oncomine database 
**Number of genes probed 
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2.2. Initial screening of microarray datasets 
Each dataset obtained from the Oncomine database contained more than one type of brain and CNS cancer. 
Hence for each dataset, sub-datasets were created based on the type of cancers it contained, location or 
treatments.  
 
2.3. Creation of sub-datasets 
Bredel Brain 2 dataset consists specimens belonging to astrocytic, glioblastomas and oligodendroglial types 
of brain tumors. Hence this dataset was divided on the basis of these tumors and their corresponding subparts. 
Six sub-datasets were created and the list is provided in Bredel Brain 2 sheet of Supplementary File1. Lee Brain 
dataset was divided based on the region from where the tumor was extracted. For instance, a separate sub-
dataset was created for each tumor cell line. Thirteen sub-datasets were created and the list is provided in Lee 
Brain sheet of Supplementary File1. Liang Brain dataset contained data from 5 different platforms. The normal 
samples belonged to GEO Platform GPL2935 and on comparison we found that platforms GPL182, GPL2778 
and GPL2935 have identical genes whereas GPL2648 and GPL3010 have different genes. So, the samples 
belonging to the latter two platforms were removed from further analysis. The sub-datasets were created on the 
basis of different types of tumors. The detailed information is provided in Liang Brain sheet of Supplementary 
File1. In Murat Brain, the dataset was divided to three sub-datasets based on the various treatments provided. 
The sub-datasets are listed in Murat Brain sheet of Supplementary File1. 
 
2.4. Identification of up-regulated genes in each sub dataset 
For each sub-dataset, Significance Analysis of Microarray (SAM) [14] was performed using the software 
Multiple experiment Viewer (MeV) [15]. The details of the output generated are provided in the Bredel Brain 2 
sheet, Lee Brain sheet, Liang Brain sheet and Murat Brain sheet of Supplementary File2 for the sub-datasets of 
Bredel Brain 2, Lee Brain, Liang Brain and Murat Brain respectively. 
 
2.5. Z score calculation 
Z score is calculated for all possible pairs of sub-datasets. The formula used is 
 
where Robs is the number of significant genes in both datasets A and B, nB is the number of genes in dataset B 
and PA is the probability of gene being significantly upregulated in A [16].  
 
2.6. Obtaining ranked list of up-regulated genes
 
For the identification of differentially expressed genes across multiple datasets, ‘rank product’ method was 
used. It is a non-parametric method implemented in the RankProd package [17] [18]. RankProd is a biologically 
intuitive algorithm and statistically rigorous, which has been shown to be robust against noise in microarray data 
[19] [20]. This algorithm is shown to have higher specificity and sensitivity as compared to other types of meta-
analytic tools for microarrays [17]. Based on the conservative estimation of the percentage of false positive 
predictions (pfp), a list of up-regulated genes is created. As recommended, a pfp value of 0.15 was used to set 
the threshold for genes that are significantly up-regulated [16]. 
 
3. RESULTS AND ANALYSIS  
 
3.1.  Congruency between microarray datasets 
        Since the dataset MBSP3 contains 0 significantly up-regulated genes hence it has not been considered in Z 
score calculation. The datasets which had pairwise z score > 1.96 were considered for further analysis. The 
selected datasets are: BB2SP1, BB2SP2, BB2SP3, BB2SP4, BB2SP5, BB2SP6, LBSP1, LBSP2, LBSP3, 
LBSP4, LBSP5, LBSP6, LBSP7, LBSP8, LBSP9, LBSP10, LBSP11, LBSP12, LBSP13. The sub-datasets 
belonging to Liang Brain and Murat Brain were thus excluded from further analysis. In Figure 1., the cells in red 
color represent values of z-score > 1.96 and in brown represent values < 1.96. 
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Figure 1. Pairwise Z score of sub-datasets 
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3.2.  Identification of upregulated genes 
Combining the result of SAM for all the selected sub-datasets, 3861 significant genes were obtained. To 
improve the result of SAM, the significant genes were further analyzed using RankProd with pfp threshold of < 
0.15. 271 genes were found to be significantly up-regulated using RankProd program and after removing 
duplicates, there were 130 significant genes. A complete ranked list of significantly up-regulated genes has been 
provided in Supplementary File3. Top 26 significantly up-regulated genes are listed in Table2. 
 
 
Table 2. List of top 26 significantly up-regulated genes 
Gene symbol Description 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 
ANXA2 annexin A2 
C1QC complement component 1, q subcomponent, C chain 
C3 complement component 3 
CHI3L2 Chitinase 3-like 2: chitinase precursor 
COL1A1 collagen, type I, alpha 1 
COL6A2 collagen, type VI, alpha 2 
CTGF connective tissue growth factor 
CXCL14 chemokine (C-X-C motif) ligand 14 
DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
GFAP glial fibrillary acidic protein 
HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 
HBB hemoglobin, beta 
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
HLA-DRA major histocompatibility complex, class II, DR alpha 
IGFBP7 insulin-like growth factor binding protein 7 
IL13RA2 interleukin 13 receptor, alpha 2 
MAGEA6 melanoma antigen family A, 6 
MEOX2 mesenchyme homeobox 2 
MGST1 microsomal glutathione S-transferase 1 
RBMS1 RNA binding motif, single stranded interacting protein 1 
RGS1 regulator of G-protein signaling 1 
SERPINA3 Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
SRGN Serglycin 
TGFBI transforming growth factor, beta-induced, 68kDa 
 
 
To enhance the validity of our findings, we searched for experimental works which prove the involvement 
of these genes in Brain and CNS cancer. It has been reported that the prognosis in primary Glioblastoma 
multiformes is highly correlated with ALDH1A3 promoter methylation [21] [22]. Studies have shown that 
ANXA2 is significantly over-expressed in glioma samples as compared to normal brain samples [23]. This gene 
regulates angiogenesis and invasion of malignant gliomas as well [24]. C3 gene expression is enhanced in time 
as well as dose dependent manner through interleukin-1 (IL-1 beta) as well as tumor necrosis factor-alpha 
(TNF-alpha) in the astroglioma cell line D54-MG [25]. CHI3L2 gene encodes a protein YKL-40 which serves 
as a prognosticator for cancer and this gene is found to be highly up-regulated in glioma [26]. COL1A1 is over-
expressed in pilomyxoid astrocytomas as well as pilocytic astrocytomas [27]. COL1A1 and COL6A2 are over-
expressed in both primary as well as meta-static brain tumors [28]. CTGF plays a significant role in gliomas. 
Studies have suggested that gene expression level of this gene can have prognostic significance [29]. GBP1 gene 
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over-expression enhances glioma cell invasion [30]. GFAP is highly expressed in tumor cells and hence can be 
used in the detection of tumor recurrence [31]. HLA-DPA1 and HLA-DRA are the important genes involved in 
Glioblastoma multiforme [32]. IGFBP7 is highly over-expressed in Glioblastoma multiforme [33] and Pilocytic 
astrocytomas [34]. IL13RA2 is over-expressed in highly invasive glioblastoma multiforme [35]. SERPINA3 
gene has been found to be involved in brain metastasis [36]. TGFBI is methylated in neuroblastoma [37]. The 
remaining top significant genes which have not been associated with brain and CNS cancer till now are: C1QC, 
CXCL14, DDX3Y, HBA1 or HBA2, HBB, MAGEA6, MEOX2, MGST1, RBMS1, RGS1, SRGN and TGFBI. 
 
3.3. Functional analysis of up-regulated genes 
       The significant genes obtained through RankProd were entered as an input to the tool “Database for 
Annotation, Visualization and Integrated Discovery”, DAVID [38] [39] which is a functional annotation tool. 
123 genes matched out of 130 genes given as an input. Functional Annotation for these 123 genes was obtained 
using the tool. Here we present the results of some of the functional annotation categories: Reactome Pathway, 
OMIM Diseases, KEGG Pathway and Genetic Association DB Disease Class. (Figures2-5) The complete results 
of Functional Annotation can be found in the Supplementary File-DAVID: Category-based sheet contains the 
information on the basis of various categories that were selected by us during the execution, Cluster-based sheet 
contains the information for the different annotation clusters generated by DAVID [38] [39] and Gene-based 
sheet contains the functional annotation information for each gene. 
 
 
 
Figure 2. Enriched Reactome Pathway obtained through DAVID [38] [39] 
 
 
 
Figure 3. Enriched OMIM Diseases obtained through DAVID [38] [39]. 
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Figure 4. Enriched KEGG PATHWAY obtained through DAVID [38] [39]. 
 
 
Figure 5. Enriched GENETIC ASSOCIATION DB DISEASE CLASS obtained through DAVID [38] [39] 
 
 
3.4. Identification of significant pathways 
       Using online tool of Genemania [40] a network was created with 127 genes as an input. The seven types of 
network which were created are: Co-expression, Co-localization, Genetic Interaction, Pathway, Physical 
Interaction, Predicted and Shared Protein Domains network. The predicted pathway contains only one 
interaction and hence was removed from further analysis. The network properties for each network was 
determined using Network analyzer tool of Cytoscape [41]. They are mentioned in the tables below. (Tables 3-
8)  
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Table 3. Network Properties of Co-expression network 
Properties Co-expression network 
Clustering Coefficient 0.177 
Connected components 2 
Network diameter 6 
Network radius 1 
Shortest paths 4288 (29%) 
Characteristic path length 2.091 
Average number of neighbors 16.639 
Number of nodes 122 
Network density 0 
Isolated nodes 0 
Number of self-loops 0 
Multi-edge node pairs 322 
Analysis time (sec) 0.085 
 
Table 4. Network Properties of Co-localization network 
Properties Co-localization network 
Clustering Coefficient 0.208 
Connected components 3 
Network diameter 4 
Network radius 1 
Shortest paths 319 (5%) 
Characteristic path length 1.639 
Average number of neighbors 4.184 
Number of nodes 76 
Network density 0 
Isolated nodes 0 
Number of self-loops 0 
Multi-edge node pairs 7 
Analysis time (sec) 0.303 
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Table 5. Network Properties of Genetic Interaction network 
Properties Genetic interaction 
Clustering Coefficient 0.08 
Connected components 1 
Network diameter 6 
Network radius 1 
Shortest paths 1951 (20%) 
Characteristic path length 2.317 
Average number of neighbors 7.204 
Number of nodes 98 
Network density 0 
Isolated nodes 0 
Number of self-loops 0 
Multi-edge node pairs 0 
Analysis time (sec) 0.067 
 
 
Table 6. Network Properties of Pathway network 
Properties Pathway 
Clustering Coefficient 0.141 
Connected components 5 
Network diameter 2 
Network radius 1 
Shortest paths 30 (4%) 
Characteristic path length 1.133 
Average number of neighbors 2 
Number of nodes 26 
Network density 0 
Isolated nodes 0 
Number of self-loops 0 
Multi-edge node pairs 1 
Analysis time (sec) 0.035 
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Table7: Network Properties of Physical Interaction network 
Properties Physical interaction 
Clustering Coefficient 0.024 
Connected components 8 
Network diameter 4 
Network radius 1 
Shortest paths 87 (6%) 
Characteristic path length 1.77 
Average number of neighbors 2.222 
Number of nodes 36 
Network density 0 
Isolated nodes 0 
Number of self-loops 0 
Multi-edge node pairs 35 
Analysis time (sec) 0.301 
 
 
Table8: Network Properties of Shared Protein Domains network 
Properties Shared protein domains 
Clustering Coefficient 0.236 
Connected components 18 
Network diameter 3 
Network radius 1 
Shortest paths 81 (2%) 
Characteristic path length 1.16 
Average number of neighbors 2.1875 
Number of nodes 64 
Network density 0 
Isolated nodes 0 
Number of self-loops 0 
Multi-edge node pairs 0 
Analysis time (sec) 0.584 
 
 
The edge details of Co-expression, Co-localization, Genetic Interaction, Pathway, Physical Interaction, 
Predicted and Shared Protein Domains network are provided in the Co-expression sheet, Co-localization sheet, 
Genetic Interaction sheet, Pathway sheet, Physical Interaction sheet, Predicted sheet and Shared Protein 
Domains sheet of Supplementary File4 respectively. The node details of Co-expression, Co-localization, 
Genetic Interaction, Pathway, Physical Interaction, Predicted and Shared Protein Domains network are provided 
in the Co-expression sheet, Co-localization sheet, Genetic Interaction sheet, Pathway sheet, Physical Interaction 
sheet, Predicted sheet and Shared Protein Domains sheet of Supplementary File5 respectively. 
        For each network, significant pathways were determined. The methodology used is as follows: Firstly, for 
each gene present in the network, we determined the KEGG pathways that are associated with that gene. The 
obtained pathways are assigned the Genemania [40] score of the corresponding gene. Now, for each pathway 
present in the network, combined score and total count of the pathway in the network is calculated. The enriched 
pathways are then classified on the basis of the pathway class of KEGG. The Supplementary File-
SIGNIFICANT PATHWAYS contains the graphical representation for enriched pathways present in each 
network. The complete list of the pathways can be found in the Supplementary File-Pathways. Here we present 
the topmost significant pathways relevant to our discussion.  
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      In co-expression network for brain and CNS cancer, top five significant pathways are Retinol metabolism; 
cAMP signaling pathway; Notch signaling pathway; Prion diseases and Signaling pathways regulating 
pluripotency of stem cells. For co-localization network, top five significant pathways are: Signaling pathways 
regulating pluripotency of stem cells; Notch signaling pathway; Intestinal immune network for IgA production; 
RIG-I-like receptor signaling pathway and Sphingolipid signaling pathway. In genetic interaction network top 
five significant pathways are: Prion diseases; Retinol metabolism; Notch signaling pathway; cAMP signaling 
pathway and Signaling pathways regulating pluripotency of stem cells. For pathway network, top five 
significant pathways are: Regulation of actin cytoskeleton; Gap junction; MAPK signaling pathway; Ras 
signaling pathway and Phospholipase D signaling pathway. In physical interaction network, top five significant 
pathways are: Gap junction; Phospholipase D signaling pathway; Glioma; Melanoma and Choline metabolism 
in cancer. In shared protein domains network, the top five significant pathways are: cAMP signaling pathway; 
Notch signaling pathway; Prion diseases; Regulation of actin cytoskeleton and Gap junction.  
 
4. CONCLUSION 
It can be concluded that meta-analysis of microarray datasets yields more comprehensive and reliable 
results as compared to a single dataset because it has generalizability and increased statistical power. On 
creating different types of networks of significantly up-regulated genes, various pathways that are possibly 
enriched in Brain and CNS cancer have been obtained. 
 
SUPPLEMENTARY FILES 
 1. Supplementary File1 
 2. Supplementary File2 
3. Supplementary File3 
4. Supplementary File4 
5. Supplementary File5 
6. Supplementary File-DAVID 
7. Supplementary File-Pathways 
8. Supplementary File-SIGNIFICANT PATHWAYS 
9. ZScore-ExcelSheet  
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